A special issue of the Federation of the European Biochemical Society (FEBS) Journal dedicated to CRISPR/Cas9 highlights nine review articles, including several MSK researchers.
- Tschaharganeh, D. F., Lowe, S. W., Garippa, R. J. and Livshits, G. (2016), Using CRISPR/Cas to study gene function and model disease in vivo. FEBS J, 283: 3194–3203. doi:10.1111/febs.13750
- Miles, L. A., Garippa, R. J. and Poirier, J. T. (2016), Design, execution, and analysis of pooled in vitro CRISPR/Cas9 screens. FEBS J, 283: 3170–3180. doi:10.1111/febs.13770
MSK is teaming up with the home of TLC’s “Say Yes to the Dress”, Kleinfeld Bridal in midtown Manhattan, to raise awareness and money for breast cancer research. Kleinfeld has agreed to donate 5% of every dress over $3,000 (the average price of a dress at Kleinfeld is $4,500 and up) to breast cancer research at MSK for brides who purchase their dress between now and October 31st. Brides shopping during this time period will also be provided with pink silk robes and shoes to celebrate breast cancer awareness.
CureToday interviewed Dr. Ghassan Abou-Alfa, MD about the new therapeutic vaccine, Pexa-Vec, for patients with advanced hepatocellular carcinoma (HCC). Dr. Abou-Alfa touched on the phase 2 study that he presented at the 10th International Liver Cancer Association Annual Conference, including using the vaccine as a second line therapy and anticipated adverse effects.
A new clinical trial through MSK and the Multiple Myeloma Research Foundation (MMRF) was announced to determine predictors of minimal residual disease (MRD) negativity. The trial is called “Carfilzomib, Lenalidomide, Dexamethasone in Newly-Diagnosed Multiple Myeloma: a Translational MRD Study”. Research has found that very low or undetectable levels of MRD are correlated with better patient outcomes, so this trial is looking to understand why some people have residual disease and figure out how to eradicate the last of the tumor cells.